SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The required radiation exposure limits safe longitudinal applications, particularly in presymptomatic studies 12.”
From Molecular design of MRI probes for targeting amyloid-β species: from in vitro binding to in vivo imaging (2026) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · cited 1×
“2 were eligible, but the study used 111 In-pentetreotide for enrollment and it is unclear how SSTR PET should be used for patient selection for PRRT ( 33 ).”
MethodSelf-citationFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2961-x · Cited by 3,303 · cited 1×
“0 (3): PET/CT: An integrated or multimodality PET/CT system is a physical combination of PET and CT that allows sequential acquisition of PET and CT portions.”
BackgroundSelf-citationHofman, M. S., Lau, W. F. E., & Hicks, R. J. (2015) · RadioGraphics · doi:10.1148/rg.352140164 · Cited by 561
Research works printed but not linked: 44
- 10.1200/JCO.2009.22.8510 · DOI · Paper page
- 10.1056/NEJMoa1316158 · DOI · Paper page
- 10.2967/jnumed.117.202275 · DOI · Paper page
- 10.2967/jnumed.120.257808 · doi:10.2967/jnumed.120.257808
- 10.1111/his.13975 · DOI · Paper page
- 10.1530/ERC-17-0005 · DOI
- 10.1007/s00259-011-2031-6 · DOI · Paper page
- Society of Nuclear Medicine and Molecular Imaging Technologist Section. Nuclear Medicine Technologist Scope of Practice and Performance Standards. 2nd Edition. Amazon aws website. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/NMT%20Scope%20of%20Practice%20and%20Performance%20Standards%202nd%20Ed-2022%20Complete-Approved_6-9-22.pdf. Approved June 9, 2022. Accessed December 1, 2022.
- Bozkurt, 2017, Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA, Eur J Nucl Med Mol Imaging., 44, 1588, 10.1007/s00259-017-3728-y · doi:10.1007/s00259-017-3728-y
- Aalbersberg, 2019, Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation, Eur J Nucl Med Mol Imaging., 46, 696, 10.1007/s00259-018-4117-x · DOI
- 10.2967/jnumed.119.226332 · doi:10.2967/jnumed.119.226332
- 10.2967/jnumed.117.192203 · DOI
- Kong, 2016, Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma, J Pediatr Hematol Oncol., 38, 87, 10.1097/MPH.0000000000000411 · DOI
- Abongwa, 2017, Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors, Am J Nucl Med Mol Imaging., 7, 228
- 10.2967/jnumed.120.244509 · doi:10.2967/jnumed.120.244509
- 10.1007/s00261-015-0409-9 · doi:10.1007/s00261-015-0409-9
- 10.2967/jnumed.112.114165 · DOI
- 10.2967/jnumed.116.180430 · DOI · Paper page
- 10.1097/RLU.0b013e31825b2555 · doi:10.1097/rlu.0b013e31825b2555
- Virgolini, 2016, Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging., 43, 2072, 10.1007/s00259-016-3395-4 · DOI
- 10.1016/S0140-6736(78)92181-5 · DOI
- Mackie, 1990, Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation, Development., 110, 1233, 10.1242/dev.110.4.1233 · DOI
- 10.1152/ajpendo.00048.2003 · DOI · Paper page
- Hope, 2019, 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden, J Nucl Med., 60, 1266, 10.2967/jnumed.118.223016 · DOI
- Kratochwil, 2015, SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors, Mol Imaging Biol., 17, 313, 10.1007/s11307-014-0795-3 · DOI · Paper page
- Werner, 2018, SSTR-RADS version 1.0 as a reporting system for SSTR-PET imaging and selection of potential PRRT candidates: a proposed standardization framework, J Nucl Med., 59, 1085, 10.2967/jnumed.117.206631 · DOI
- Öksüz, 2014, Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?, Diagn Interv Imaging., 95, 289, 10.1016/j.diii.2013.07.006 · DOI
- 10.1245/s10434-015-4471-x · doi:10.1245/s10434-015-4471-x
- Reubi, 1990, Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas, Cancer Res., 50, 5969
- Graf, 2020, Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE, Eur J Nucl Med Mol Imaging., 47, 881, 10.1007/s00259-019-04439-9 · DOI
- Werner, 2019, Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy, Mol Imaging Biol., 21, 582, 10.1007/s11307-018-1252-5 · DOI
- Werner, 2017, Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity, Oncotarget., 8, 7039, 10.18632/oncotarget.12402 · DOI
- 10.1002/cncr.23469 · DOI · Paper page
- Hindié, 2017, The NETPET Score: combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors, Theranostics., 7, 1159, 10.7150/thno.19588 · DOI
- Binderup T Knigge U Johnbeck CB . 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients. J Nucl Med. 2021; 62:808–815. · DOI
- 10.1102/1470-7330.2010.9007 · DOI
- Chan, 2017, Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance, Theranostics., 7, 1149, 10.7150/thno.18068 · DOI · Paper page
- 10.2967/jnumed.106.035667 · DOI · Paper page
- 10.2967/jnumed.115.156539 · DOI
- 10.1200/JCO.2015.64.0987 · DOI · Paper page
- Hartmann, 2009, Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations [in German], Nucl Med (Stuttg)., 48, 201
- 10.2967/jnumed.111.101469 · DOI · Paper page
- Brix, 2005, Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations, J Nucl Med., 46, 608
- Kratochwil, 2015, Comparison of 68Ga-DOTATOC biodistribution in patients with and without splenectomy, Q J Nucl Med Mol Imaging., 59, 116
Cited by
Shi, Y., Zhang, R., Li, M., Xia, Y., Zhou, M., Cao, R., Zhou, Q., & Zhang, Y. (2026) · Theranostics · doi:10.7150/thno.131311
“The required radiation exposure limits safe longitudinal applications, particularly in presymptomatic studies [12].”
Metadata
- Authors
- Hope, T. A., Allen-Auerbach, M., Bodei, L., Calais, J., Dahlbom, M., Dunnwald, L. K., Graham, M. M., Jacene, H. A., Heath, C. L., Mittra, E. S., Wright, C. L., Fendler, W. P., Herrmann, K., Taïeb, D., & Kjaer, A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2023-02
- Volume
- 64
- Issue
- 2
- Pages
- 204-210
- ISSN
- 0161-5505
- 2159-662X
- Cited by
- 144
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. https://app.cochat.ai/papers/10.2967/jnumed.122.264860
- The paper
- Hope, T. A., Allen-Auerbach, M., Bodei, L., Calais, J., Dahlbom, M., Dunnwald, L. K., Graham, M. M., Jacene, H. A., Heath, C. L., Mittra, E. S., Wright, C. L., Fendler, W. P., Herrmann, K., Taïeb, D., & Kjaer, A. (2023). SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.264860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.